HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

Trevi Therapeutics (NASDAQ:TRVI) had its price target hoisted by investment analysts at HC Wainwright from $6.00 to $7.50 in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 79.86% from the company’s current price. HC Wainwright also issued estimates for Trevi Therapeutics’ FY2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.38) EPS.

A number of other brokerages also recently commented on TRVI. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Thursday. Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Raymond James began coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Thursday. Finally, Leerink Partners began coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Stock Up 15.8 %

Shares of Trevi Therapeutics stock opened at $4.17 on Thursday. The firm has a market cap of $320.53 million, a price-to-earnings ratio of -9.48 and a beta of 0.96. The business has a 50-day moving average price of $2.97 and a 200-day moving average price of $2.92. Trevi Therapeutics has a twelve month low of $1.22 and a twelve month high of $4.60.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter in the previous year, the firm posted ($0.08) earnings per share. On average, equities analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Logos Global Management LP lifted its stake in Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after acquiring an additional 60,249 shares during the period. Bank of New York Mellon Corp increased its position in shares of Trevi Therapeutics by 38.8% during the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock worth $532,000 after acquiring an additional 49,884 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in shares of Trevi Therapeutics during the first quarter worth approximately $47,000. Finally, Ally Bridge Group NY LLC purchased a new position in shares of Trevi Therapeutics during the second quarter worth approximately $4,395,000. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.